DUBLIN, April 3, 2019 /PRNewswire/ -- Alkermes
plc (Nasdaq: ALKS) today announced the next evolution of the
ALKERMES PATHWAYS RESEARCH AWARDSSM program, an
initiative designed to support the next generation of researchers
who are working on the front lines to advance understanding and
awareness of central nervous system (CNS) disorders. The program
will continue to support projects focused on helping those living
with substance use disorders (SUDs) and is expanding to include
projects dedicated to helping people living with schizophrenia. The
current application cycle will run through July 31, 2019.
"The Pathways program exemplifies our company's commitment to
helping researchers find unique and meaningful ways to impact the
people and communities we serve with our medicines," said
Craig Hopkinson, M.D., Chief Medical
Officer and Senior Vice President of Medicines Development and
Medical Affairs at Alkermes. "We are optimistic that expanding the
program to include projects supporting schizophrenia will bring
additional innovation and advances in research to this scientific
and clinical community."
Now open to early-career investigators committed to advancing
research in SUDs and/or schizophrenia, the second annual Pathways
program grants will provide funding for up to eight research
projects with individual grant amounts of up to $100,000 per project. Alkermes has reserved four
awards for research focused on SUDs and four awards for research
focused on schizophrenia.
"The Pathways grant that I received last year allowed
me to jumpstart my research project and career in a way that
otherwise might not have been possible," said Derek Blevins, M.D., Columbia University, New
York State Psychiatric Institute and
inaugural Alkermes Pathways award grantee.
"Alkermes investing in young scientists like me to bring
research projects to fruition really demonstrates the
company's commitment to building a better future for people living
with debilitating CNS disorders."
To qualify, early-career investigators must be M.D.s, Ph.D.s or
equivalent, who are within five years of their initial academic
appointment or are currently post-doctoral fellows, and who are
affiliated with a medical or research center within the United States. Full eligibility criteria
are available on the program website here.
About Alkermes plc
Alkermes plc is a
fully integrated, global biopharmaceutical company developing
innovative medicines for the treatment of central nervous system
(CNS) diseases. The company has a diversified commercial product
portfolio and a substantial clinical pipeline of product candidates
for chronic diseases that include schizophrenia, depression,
addiction, multiple sclerosis and oncology. Headquartered
in Dublin, Ireland, Alkermes plc has an R&D
center in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and a manufacturing facility
in Wilmington, Ohio. For more
information, please visit Alkermes' website
at www.alkermes.com.
Note Regarding Forward-Looking Statements
Certain
statements set forth in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning the expected timing,
operation and potential impact of, and awards of funding by,
the ALKERMES PATHWAYS RESEARCH
AWARDSSM program, and the nature of the research to
be supported by such funding. The company cautions that
forward-looking statements are inherently uncertain. Although the
company believes that such statements are based on reasonable
assumptions within the bounds of its knowledge of its business and
operations, the forward-looking statements are neither promises nor
guarantees and they are necessarily subject to a high degree of
uncertainty and risk. Actual performance and results may differ
materially from those expressed or implied in the forward-looking
statements due to various risks and uncertainties. These risks and
uncertainties include, among others, changes in funding, timing or
parameters of the ALKERMES PATHWAYS RESEARCH AWARDS program, the
nature of any findings or results arising from the research
supported by the program and those risks and uncertainties
described under the heading "Risk Factors" in the company's Annual
Report on Form 10-K for the year ended Dec.
31, 2018 and in subsequent filings made by the company with
the U.S. Securities and Exchange Commission (SEC), which are
available on the SEC's website at www.sec.gov. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. Except as required by law, the company disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release.
ALKERMES PATHWAYS RESEARCH AWARDSSM is a service mark
of Alkermes, Inc.
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609
6377
For Media: Sherry
Feldberg, +1 781 609 6276
View original content to download
multimedia:http://www.prnewswire.com/news-releases/alkermes-expands-awards-program-with-focus-on-advancing-research-in-schizophrenia-300823492.html
SOURCE Alkermes plc